Fluicell AB (publ) (STO:FLUI)

Market Cap	18.34M -2.6%
Revenue (ttm)	15.22M +184.5%
Net Income	-8.33M
EPS	-6.07
Shares Out	1.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,971
Average Volume	4,114
Open	13.10
Previous Close	13.05
Day's Range	13.10 - 13.60
52-Week Range	7.45 - 30.00
Beta	1.35
RSI	54.15
Earnings Date	Apr 8, 2026

About Fluicell AB

Fluicell AB (publ) operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. The company offers BIOPEN, a microfluidic platform for high-precision single-cell solution delivery that enables to control the cell microenvironment without moving or disturbing the cells; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch-clam...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 11
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: FLUI

Financial Performance

In 2025, Fluicell AB's revenue was 15.22 million, an increase of 184.54% compared to the previous year's 5.35 million. Losses were -8.33 million, -46.28% less than in 2024.